Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
106P - The value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma (ID 472)
12:30 - 13:00 | Author(s): H. Zhong
The adjuvant chemotherapy(ACT) of stage IB lung adenocarcinoma remain controversial, and solid ingredients were supposed to be connected to the poor survival. We are intended to explore the benefits adjuvant chemotherapy made on patients in IB with solid ingredients.
a number of 334 completely resected patients with lung adenocarcinoma in stage IB from 2006 to 2015 were reviewed. All the pathological slides were evaluated with solid ingredients composed.
Our data showed that although disease-free survival (DFS)(p = 0.661) and overall survival (OS)(p = 0.130) were not significantly different in solid growth pattern with or without ACT, patients with solid predominant patterns tend to have longer DFS [hazard ratio (HR) 0.403, p = 0.021)]and OS (HR 0.286, p = 0.009) with ACT. In patients with solid non-predominant patterns, receiving ACT had little influence in DFS(p = 0.231) and OS (p = 0.611).
the solid predominant pattern in postoperative patients of stage IB could benefit from adjuvant, and solid non-predominant pattern couldn't.
Clinical trial identification:
Legal entity responsible for the study:
Shanghai chest hospital
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.